Reading Room

Guidant Ancure Endograft System

Jon 8105

What is the Gnidant Ancure Endograft System? The Ancure Devise was designed for use in the treatment of abdominal aortic aneurysms. An abdominal aortic aneurysm is a potentially life threatening condition involving a weak area that develops in the wall of the aorta, the artery that brings blood flow from the heart through the abdomen to the rest of the body. The Aneure Device sold by Guidant has two primary parts. 

Guidant Ancure Endograft System

Jon 8095

What is the Gnidant Ancure Endograft System? The Ancure Devise was designed for use in the treatment of abdominal aortic aneurysms. An abdominal aortic aneurysm is a potentially life threatening condition involving a weak area that develops in the wall of the aorta, the artery that brings blood flow from the heart through the abdomen to the rest of the body. The Aneure Device sold by Guidant has two primary parts. 

Enbrel and Remicade Companies Sued for Infections and Deaths

Jon 7266

In August one of the first cases was filed against the manufacturer of the biological product, Enbrel (etanercept). Enbrel (etanercept) was approved by the U.S. Food and Drug Administration on November 2, 1998, as a second-line agent for the treatment of juvenile rheumatoid arthritis. At the time Enbrel was co-marketed by Immunex, Corp. 

Enbrel and Remicade Companies Sued for Infections and Deaths

Jon 7260

In August one of the first cases was filed against the manufacturer of the biological product, Enbrel (etanercept). Enbrel (etanercept) was approved by the U.S. Food and Drug Administration on November 2, 1998, as a second-line agent for the treatment of juvenile rheumatoid arthritis. At the time Enbrel was co-marketed by Immunex, Corp. 

Warnings Issued for Remicade (Infliximab)used For Rheumatoid Arthritis and Crohn's

Jon 6819

Remicade (Infliximab) is an immune-suppressing product manufactured by Centocor, a wholly owned subsidiary of Johnson & Johnson, which has been approved by the U.S. Food and Drug Administration for the use for Crohn's disease and rheumatoid arthritis. Remicade is a worldwide market share leader among tumor necrosis factor alpha therapies and is the only biologic drug indicated for the treatment of both Rheumatoid Arthritis and Crohns' disease.

Warnings Issued for Remicade (Infliximab)used For Rheumatoid Arthritis and Crohn's

Jon 6819

Remicade (Infliximab) is an immune-suppressing product manufactured by Centocor, a wholly owned subsidiary of Johnson & Johnson, which has been approved by the U.S. Food and Drug Administration for the use for Crohn's disease and rheumatoid arthritis. Remicade is a worldwide market share leader among tumor necrosis factor alpha therapies and is the only biologic drug indicated for the treatment of both Rheumatoid Arthritis and Crohns' disease.

Remicade (Infliximab) Warning Letter from Centocor to Health Care Frofesssionals 10/18/2001

Jon 5063

 Centocor October 18, 2001 IMPORTANT DRUG WARNING
Dear Healthcare Professional:
Centocor, Inc. would like to inform you of important new safety information for REMICADE® (infliximab). Upon review of preliminary results of its ongoing phase 2 trial in 150 patients with moderate to severe (NYHA class III-IV) congestive heart failure (CHF), higher incidences of mortality and hospitalization for worsening heart failure were seen in patients...

Remicade (Infliximab) Warning Letter from Centocor to Health Care Frofesssionals 10/18/2001

Jon 5061

 Centocor October 18, 2001 IMPORTANT DRUG WARNING
Dear Healthcare Professional:
Centocor, Inc. would like to inform you of important new safety information for REMICADE® (infliximab). Upon review of preliminary results of its ongoing phase 2 trial in 150 patients with moderate to severe (NYHA class III-IV) congestive heart failure (CHF), higher incidences of mortality and hospitalization for worsening heart failure were seen in patients...

Medtronic Announces Defect in Sprint Fidelis Defibrillation Leads

Jon 4790

On October 14, 2007, Medtronic, the nation's largest heart implant device manufacturer, announced a defect in the critical electrical "lead" component of its heart defibrillator. The New York Times reported on October 15, 2007, that the defect in this electrical wire, called the Sprint Fidelis, has resulted in hundreds of malfunctions and may have played a role in the death of five Medtronic defibrillator patients.
 

1234567

CONTACT US
1.973.696.7900
jon.gelman@gmail.com